About APC
​About Access Pharma Consulting
Market Access & Regulatory Strategy for France
​​​​
Access Pharma Consulting is a France-based market access and regulatory consulting firm supporting pharmaceutical, biotech, medical device, and medical cannabis companies entering or expanding in the French market.
​
We provide senior-level regulatory strategy, market access planning, pricing and reimbursement expertise, and stakeholder engagement support aligned with ANSM and HAS requirements.
​
Our consultancy supports international healthcare companies across specialty and hospital-driven markets, addressing complex French regulatory pathways and access challenges.
​
With over 10 years of pharmaceutical industry leadership, Access Pharma Consulting combines medical expertise, regulatory intelligence, and commercial strategy to accelerate successful market entry in France.
​
We work directly with executive teams to design decision-ready, locally grounded, and globally aligned go-to-market strategies for France.
More than navigating the French healthcare system, we unlock it.
Strategic Market Access &
Regulatory Services
Tailored Expertise Across the Pharmaceutical & Biotech Product Journey
At APC, we design and deliver high-level market access and regulatory strategies tailored to your product, development stage, and market objectives.
​
Whether you're exploring the French market, preparing a launch, or refining your access strategy, we align medical, regulatory, and commercial dimensions to unlock success.
Why Choose Access Pharma Consulting for Market Access ?
Led by Dr. Dounia Farajallah, PharmD & ESSEC-trained strategist, with a strong pharmaceutical industry background, combining medical insight with executive-level business and market access expertise.
More than 12 years of experience in the pharmaceutical industry, including leadership roles across international environments and hands-on involvement in the launch and management of a French subsidiary for a global pharma group.
Proven experience in regulatory approvals, market access strategy, and pricing negotiations across complex therapeutic areas.
Deep mastery of the French healthcare system, including ANSM and HAS interactions, reimbursement pathways, and hospital tenders.
Acting as a single senior interface to accelerate decision-making, reduce regulatory risk, and avoid costly misalignment between medical, regulatory and commercial teams across complex products and markets.
